surmount-1 trial tirzepatide weight loss non-diabetic for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled Tirzepatide Demonstrates 94% Diabetes Reduction,

Consider asking any patients about their use of online products including peptides

17.2 Severe Gastrointestinal Symptoms and Hypoglycemia Risk Symptoms may include: Persistent nausea and vomiting Severe dehydration Hypoglycemia, particularly with concomitant therapy 17.3 Immediate Management and Supportive Care There is no specific antidote

The lactation studies suggest minimal risk from injectable semaglutide and tirzepatide, but the safest approach during partial weaning depends on how much the infant is still relying on breast milk

Can Any Weight Loss Occur in the First Week of Semaglutide

For now, the study provides reassurance, not a green light to continue GLP-1 medications during pregnancy without medical guidance.